Guardant Health, Inc. (NASDAQ: GH) has secured European CE marking under the In Vitro Diagnostic Medical Devices Regulation for Guardant360 CDx as a companion diagnostic for AstraZeneca PLC’s ETCAMAH (camizestrant), extending blood-based ESR1 mutation testing to support treatment selection in advanced breast cancer. Announced on October 8, 2026, the certification covers the identification of patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from camizestrant, a selective estrogen receptor degrader used with a cyclin-dependent kinase 4/6 inhibitor.
The regulatory development establishes a European companion diagnostic pathway for a treatment strategy that uses circulating tumour DNA to identify emerging endocrine resistance before conventional imaging demonstrates disease progression. Rather than waiting for radiographic worsening, clinicians can use molecular information to identify eligible patients for a treatment change while continuing CDK4/6 inhibition. This approach was evaluated in the pivotal Phase 3 SERENA-6 trial, which demonstrated significantly longer progression-free survival when patients with newly detected ESR1 mutations switched from an aromatase inhibitor to camizestrant.
The European certification follows previous Guardant360 CDx approvals for the same drug in the United States and Japan, bringing the company’s reported cumulative companion diagnostic approvals to 31. Importantly, the October announcement concerns the diagnostic device rather than a new European marketing authorisation for ETCAMAH. The medicine had already received European Commission marketing authorisation on July 20, 2026, following a positive European Medicines Agency committee opinion in May.
The wider significance lies in moving liquid biopsy from a test commonly used when treatment resistance becomes clinically evident towards a monitoring tool that can guide an earlier therapeutic decision. However, identifying a mutation in circulating tumour DNA is not equivalent to diagnosing radiographic progression, and the clinical value of the strategy depends on the exact treatment setting, analytical performance and evidence supporting the subsequent intervention. Guardant Health’s latest certification strengthens the infrastructure for this model but does not establish that routine molecular monitoring will benefit every patient with advanced breast cancer.
Why does Guardant360 CDx testing before radiographic progression matter for advanced breast cancer?
The central clinical opportunity involves detecting resistance to endocrine therapy before that resistance produces measurable tumour progression. In estrogen receptor-positive breast cancer, ESR1 mutations can emerge during treatment with aromatase inhibitors, altering estrogen receptor activity and reducing dependence on the estrogen signalling pathways targeted by those medicines. Detecting these mutations through circulating tumour DNA allows clinicians to identify a molecular change while the existing treatment may still be controlling the disease on conventional imaging.
Historically, many treatment changes in advanced breast cancer have followed radiographic progression, worsening symptoms or other established evidence that the current regimen is no longer adequately controlling disease. Serial molecular testing introduces the possibility of recognising an emerging resistance mechanism earlier and acting on that information before progression becomes visible. However, the existence of a detectable mutation does not automatically establish that every patient requires a treatment change, since the clinical value depends on whether a tested intervention improves relevant outcomes.
The SERENA-6 programme provides the evidence supporting this particular approach. Patients receiving first-line aromatase inhibitor therapy with a CDK4/6 inhibitor underwent repeated circulating tumour DNA assessments, with treatment switching triggered by newly detected ESR1 mutations in the absence of disease progression. The strategy is therefore more specific than routine liquid biopsy surveillance: it combines a defined patient population, an actionable biomarker and a treatment supported by randomised clinical evidence.
This development may encourage greater integration of molecular monitoring into oncology practice, but its applicability remains limited to the settings supported by the clinical evidence and authorised treatment indications. Patients with other resistance mechanisms, different breast cancer subtypes or disease that has already progressed may require different testing and treatment strategies. The new European certification does not establish Guardant360 CDx as a universal monitoring test capable of directing all breast cancer treatment decisions.
What did the SERENA-6 Phase 3 trial establish about camizestrant and ESR1-guided treatment switching?
The Phase 3 SERENA-6 trial evaluated whether changing endocrine therapy at the emergence of an ESR1 mutation could improve outcomes before conventional disease progression. The global, randomised, double-blind study enrolled 315 eligible patients, assigning 157 to camizestrant plus continued CDK4/6 inhibition and 158 to continued aromatase inhibitor therapy with a CDK4/6 inhibitor. Patients had previously received first-line endocrine treatment with a CDK4/6 inhibitor and were selected after molecular testing identified an emerging ESR1 mutation without radiographic progression.
The original pivotal analysis demonstrated median progression-free survival of 16.0 months in the camizestrant combination group compared with 9.2 months among patients continuing aromatase inhibitor treatment. The hazard ratio for disease progression or death was 0.44, corresponding to a 56% relative reduction in the measured hazard during the evaluation period. The findings were statistically significant and were published in The New England Journal of Medicine, providing peer-reviewed evidence supporting the treatment-switching strategy.
Updated findings presented by AstraZeneca in June 2026 provided additional follow-up and strengthened the evidence of sustained disease control. Median progression-free survival reached 16.8 months with camizestrant compared with 9.2 months in the control group, producing a hazard ratio of 0.45. The updated analysis was consistent with the original primary finding, although the additional progression-free survival assessment was descriptive rather than a new independently prespecified primary endpoint test.
The longer follow-up also demonstrated improvement in second progression-free survival, an endpoint that evaluates disease progression following subsequent treatment or death. Median second progression-free survival was 25.7 months with the camizestrant combination compared with 19.1 months in the control group, with a hazard ratio of 0.63 and a reported p-value of 0.00373. This result provides evidence that the benefits of early switching were not confined solely to the first progression assessment.
Overall survival evidence remains less conclusive. In the June 2026 analysis, the reported overall survival hazard ratio was 0.87, with a 95% confidence interval ranging from 0.57 to 1.30, meaning a statistically established survival advantage had not been demonstrated at that analysis. The results therefore support improved progression-related outcomes, but should not be described as proof that the strategy extends patients’ lives.
For Guardant Health, the relevance is that molecular testing was integral to the intervention evaluated in SERENA-6. The benefit was demonstrated in patients identified through a defined circulating tumour DNA monitoring approach, rather than through an unselected population receiving camizestrant irrespective of mutation status. This provides a stronger clinical foundation for a companion diagnostic than a test whose only established role is identifying the presence of a genomic alteration without evidence supporting a corresponding treatment decision.
How does European IVDR CE marking differ from FDA approval for Guardant360 CDx?
Guardant Health’s October 8 announcement confirms that Guardant360 CDx received CE marking under the European Union’s In Vitro Diagnostic Medical Devices Regulation for its specified companion diagnostic use with ETCAMAH. This establishes conformity with the applicable European regulatory requirements for the covered intended purpose. It should not be described as an FDA-style approval of the entire Guardant360 platform for every possible genomic testing application.
The European regulatory framework distinguishes medicinal product authorisation from conformity assessment of an associated diagnostic device. ETCAMAH received European Commission marketing authorisation on July 20, 2026, following a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on May 21. The subsequent Guardant360 CDx certification provides an additional recognised diagnostic option for identifying patients eligible for the authorised treatment strategy.
Under the In Vitro Diagnostic Medical Devices Regulation, companion diagnostics are subject to conformity assessment involving a notified body, with a defined consultation process concerning their suitability for the corresponding medicinal product. These requirements are intended to ensure that patient-selection tests are evaluated for their intended clinical purpose rather than being treated merely as general laboratory technologies. The regulatory process therefore considers the relationship between the test and the therapeutic decision it supports.
The approved European ETCAMAH indication is specific. The medicine is authorised in combination with palbociclib, ribociclib or abemaciclib for adults with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer following detection of an ESR1 mutation and without disease progression during first-line endocrine therapy combined with a CDK4/6 inhibitor. This is not a general authorisation for camizestrant use in all ESR1-mutated breast cancers or after any previous treatment regimen.
In the United States, the Food and Drug Administration approved Guardant360 CDx for ETCAMAH patient selection on September 4, 2026, alongside the accelerated approval of the corresponding drug regimen. The European medicinal product authorisation and the United States accelerated approval should not be treated as identical regulatory decisions, even though both rely substantially on SERENA-6. Guardant Health also reports a prior Japanese companion diagnostic approval, establishing the three-market regulatory presence described in its latest announcement.
Can repeated liquid biopsy testing reliably identify ESR1 resistance mutations before cancer progresses?
Guardant360 CDx uses blood-derived circulating tumour DNA to identify genomic alterations relevant to oncology treatment decisions. Unlike a tissue biopsy, which examines material obtained from a particular tumour location, liquid biopsy analyses fragments of tumour DNA circulating in the bloodstream. This approach can support repeat molecular assessments without requiring a new invasive tumour-sampling procedure at every monitoring interval.
The SERENA-6 trial incorporated circulating tumour DNA testing alongside routine imaging assessments, generally at intervals of approximately two to three months. The purpose was to identify emerging ESR1 resistance mutations while patients remained on first-line aromatase inhibitor and CDK4/6 inhibitor treatment. Guardant Health has also described approximately three-monthly monitoring in the context of the United States companion diagnostic approval, although European implementation must follow the applicable product information and clinical requirements.
Repeated testing introduces analytical considerations that differ from one-time genomic profiling. Tumours may release varying quantities of DNA into the bloodstream depending on tumour burden, disease location, treatment response and underlying biological characteristics. A sample containing little detectable circulating tumour DNA can therefore produce a negative molecular result even when a relevant mutation is present but below the assay’s detection capability.
The exact analytical sensitivity and specificity for the certified ESR1 companion diagnostic use are important for interpreting such results. The October 8 announcement does not provide a detailed performance table, including variant-level detection limits, false-negative rates or prospective real-world concordance with tissue testing. Consequently, the European CE marking should not be interpreted as evidence that the assay detects every clinically relevant ESR1 mutation under all sampling conditions.
Another consideration is the distinction between identifying a specific resistance mutation and providing a complete account of tumour biology. ESR1 represents an important mechanism of resistance to aromatase inhibitor therapy, but other genetic alterations and non-genetic processes can also influence treatment response. A negative ESR1 result does not establish that the current treatment will remain effective indefinitely, while a positive result must be interpreted within the authorised treatment pathway.
These limitations do not negate the value demonstrated in SERENA-6. Instead, they explain why successful clinical implementation requires validated laboratory processes, appropriate specimen handling, timely reporting and clear procedures for acting on results. The diagnostic’s clinical usefulness depends not only on identifying a mutation but also on delivering reliable information early enough to support the intended treatment decision.
What safety considerations remain when camizestrant is introduced before disease progression?
The decision to change treatment before radiographic progression introduces an important clinical trade-off because patients may still be benefiting from their existing regimen. Any new treatment strategy must therefore demonstrate that the additional disease-control benefit justifies its safety profile, monitoring requirements and potential effects on daily functioning. SERENA-6 provides randomised evidence supporting the camizestrant combination, but its tolerability remains a relevant component of treatment selection.
The European Medicines Agency identifies neutropenia, infections, diarrhoea, nausea, anaemia, fatigue, leucopenia, visual disturbances and bradycardia among adverse effects associated with ETCAMAH in combination with CDK4/6 inhibitors. Visual effects, including photopsia, and bradycardia are particularly relevant to camizestrant, while several blood-related adverse events are associated with the CDK4/6 inhibitor component. The regulatory assessment concluded that the medicine’s benefits outweighed its risks within the authorised population, with appropriate warnings and monitoring recommendations.
The initial SERENA-6 publication reported low discontinuation rates due to adverse events in both treatment groups, approximately 1.3% with camizestrant and 1.9% with continued aromatase inhibitor treatment. These findings support tolerability within the controlled trial, but the relatively small number of randomised patients limits assessment of uncommon adverse effects. Continued safety monitoring remains important as treatment expands to broader populations with different comorbidities and medication histories.
The European authorisation also contains specific treatment considerations for premenopausal and perimenopausal women and for men, including concomitant treatment with a luteinising hormone-releasing hormone agonist or antagonist. These requirements further illustrate why the molecular finding alone does not determine treatment suitability. Patient selection must integrate biomarker status with the full authorised indication and individual clinical assessment.
Will reimbursement and laboratory capacity determine how quickly Guardant360 CDx expands across Europe?
European conformity assessment removes an important regulatory barrier, but the pace of adoption will depend on how molecular testing is incorporated into national and regional healthcare systems. European countries differ in diagnostic reimbursement, laboratory commissioning, oncology treatment pathways and the availability of advanced genomic testing. A CE-marked companion diagnostic can be eligible for its intended use without automatically securing universal reimbursement or uniform access across every market.
Repeated testing creates a different economic proposition from conventional one-time tumour profiling. A healthcare system considering serial ESR1 monitoring must account for the cost of individual tests, specimen collection, laboratory processing, reporting infrastructure and the clinical resources needed to interpret results. The relevant economic assessment also needs to consider whether earlier molecularly guided treatment changes improve outcomes sufficiently to justify those additional activities.
Operational timing will be particularly important because the strategy is intended to detect resistance before radiographic progression. A clinically actionable ESR1 result must be available while the patient still meets the treatment criteria, requiring coordination between oncology teams and the diagnostic provider. Delayed reporting or fragmented clinical workflows could reduce the practical value of a testing programme even when its analytical performance is satisfactory.
Healthcare providers will also need to establish protocols for interpreting negative, positive or inconclusive results and coordinating testing with routine imaging. These processes may involve centralised laboratory services, institutional electronic health records and multidisciplinary oncology teams. Guardant Health has not disclosed comprehensive European reimbursement coverage, country-level testing volumes or a quantified commercial rollout forecast associated with the new certification.
The availability of an authorised treatment creates a stronger rationale for reimbursing molecular testing, but the relationship is not automatic. Health technology assessment bodies and payers may examine the clinical evidence, expected testing frequency and incremental costs associated with implementing the strategy. National access decisions and the integration of liquid biopsy into routine care will therefore be central to determining how widely the newly certified diagnostic is used.
How does the 31st companion diagnostic approval strengthen Guardant Health’s competitive position?
Guardant Health describes the European ETCAMAH certification as its 31st companion diagnostic approval across its portfolio. That figure reflects cumulative approvals associated with its diagnostic platform and therapeutic partnerships, rather than 31 distinct medicines or an equivalent number of newly launched commercial products. Nevertheless, the milestone indicates continued regulatory expansion of its molecular testing capabilities across multiple oncology settings.
Guardant360 CDx already supports authorised companion diagnostic applications involving non-small cell lung cancer, breast cancer and colorectal cancer. Its broader platform can detect several classes of genomic alterations, although each specific companion diagnostic indication must be considered according to its applicable regulatory authorisation. The latest ESR1 indication adds a use case centred on longitudinal monitoring and treatment adaptation, rather than solely selecting therapy at a conventional treatment transition.
This distinction could have commercial implications because serial testing potentially involves multiple assessments during a patient’s treatment course. A diagnostic model based on repeat monitoring may generate different testing volumes and operational requirements from one-time comprehensive genomic profiling. However, the number of tests performed per patient will depend on clinical protocols, treatment duration, reimbursement and the proportion of patients who remain eligible for surveillance.
Guardant Health’s existing oncology business provides a commercial foundation for this expansion. During the second quarter of 2026, the company reported oncology revenue of $219.1 million, an increase of 38% year over year, supported by approximately 104,000 oncology tests. Oncology test volume increased 63% compared with the corresponding period of 2025, indicating substantial growth in utilisation across the company’s oncology testing activities.
Total second-quarter revenue reached $335 million, representing 44% year-over-year growth. Guardant Health also increased its full-year 2026 revenue guidance to between $1.34 billion and $1.36 billion, reflecting expectations for continued expansion across oncology, screening and related business activities. These figures provide context for the company’s operating scale, but they should not be interpreted as revenue specifically attributable to ETCAMAH companion diagnostic testing.
Competition remains relevant as other molecular diagnostics providers develop or commercialise assays capable of identifying ESR1 mutations. Regulatory certification, analytical performance, reimbursement and laboratory access will influence how diagnostic providers compete for testing volumes. Guardant Health’s advantage will depend partly on converting its regulatory authorisations and pharmaceutical partnerships into accessible, efficiently delivered clinical testing services.
How did Guardant Health shares respond to the European companion diagnostic announcement?
Guardant Health shares closed at approximately $167.47 on the Nasdaq on October 9, 2026, increasing 1.15% from the previous session’s closing price of $165.56. The stock traded between approximately $166.03 and $170.81 during the session, demonstrating a modest rebound following earlier volatility. The share-price movement followed the October 8 announcement, although there is insufficient evidence to attribute the gain specifically to the European regulatory milestone.
The broader trading context is relevant because Guardant Health shares had experienced substantial fluctuations earlier in October, including a decline of approximately 8.8% on October 6. The subsequent improvement does not establish a sustained change in investor sentiment towards the company’s liquid biopsy operations. Market expectations also reflect its colorectal cancer screening business, oncology testing growth, financial performance and future profitability.
For investors assessing the latest certification, the immediate financial impact is difficult to quantify without information on European testing volumes, pricing or reimbursement. The approval adds another potential source of diagnostic demand, but its contribution will depend on the commercial adoption of molecular monitoring and the extent to which Guardant Health captures that activity. It is therefore more appropriately viewed as a regulatory and market-access development than as evidence of an immediate earnings improvement.
The company’s next scheduled financial reporting milestone is November 5, 2026, when it expects to publish third-quarter results. Those figures may provide updated information about oncology testing momentum and overall business performance, although a separately disclosed ETCAMAH-related revenue contribution is not guaranteed. Investors will need to distinguish established testing growth from prospective demand associated with newly certified indications.
What should oncologists and diagnostic companies watch as ESR1-guided treatment becomes available across Europe?
The next stage for Guardant Health will involve translating the European companion diagnostic certification into routine testing activity across eligible oncology practices. That will require coordination with laboratories, healthcare providers and reimbursement stakeholders, particularly because the intended clinical strategy depends on obtaining molecular results before disease progression. Actual utilisation will provide a more meaningful measure of adoption than the number of regulatory authorisations alone.
For AstraZeneca, the commercial and clinical opportunity lies in increasing appropriate access to ETCAMAH within its authorised treatment setting. The medicine’s approval provides evidence-based therapeutic action following identification of emerging ESR1 resistance, while the companion diagnostic supplies an important part of the patient-selection process. The companies’ relationship illustrates how drug development and diagnostic validation can become increasingly interdependent when treatment decisions rely on dynamic molecular information.
Further clinical evidence will also shape how molecular monitoring is incorporated into treatment guidelines and institutional practice. Longer-term SERENA-6 follow-up, particularly overall survival results, will help clarify the full clinical consequences of switching endocrine therapy before radiographic progression. Additional research may examine whether comparable monitoring strategies are useful for other resistance mechanisms or therapeutic combinations, although benefits established for camizestrant cannot automatically be extended to unrelated medicines.
The October certification establishes Guardant360 CDx as a European companion diagnostic option for a specific, authorised use of ETCAMAH. Its wider significance is the emergence of a treatment pathway in which molecular evidence of resistance can support an intervention before conventional imaging identifies disease progression. Whether that approach becomes a routinely accessible component of advanced breast cancer care across Europe will depend on diagnostic reliability, reimbursement, clinical workflow integration and continued evidence that earlier treatment adaptation produces sustained patient benefit.
